Kate Excoffon | Founder and CEO
Gene Tx Optimized, LLC

Kate Excoffon is the VP of Research at Spirovant Sciences, Inc, a company focused on gene therapy for respiratory diseases. With over 25 years of experience in gene therapy in the academic and biotech space, Kate’s passion is creating, building, and advancing viral vector-mediated gene therapy. Early academic discoveries led to Glybera, the first gene therapy approved in the Western world. Later work led to the discovery of novel AAV vectors for the airway and CD4+ T cells. With over 50 publications, hundreds of presentations, numerous grants, patents, trainees, and non-clinical gene therapy drug development including regulatory document experience and success, she is a recognized expert in AAV, adenovirus, and lentivirus-based vectors, basic cellular and molecular virology, and gene therapy drug development.